We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+1.54%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$79.7M
AUM Growth
-$662M
Cap. Flow
-$660M
Cap. Flow %
-828.28%
Top 10 Hldgs %
21.47%
Holding
303
New
144
Increased
52
Reduced
48
Closed
59

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$1.36M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$1.1M
3
UPW icon
ProShares Ultra Utilities
UPW
+$905K
4
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$786K
5
PBYI icon
Puma Biotechnology
PBYI
+$617K

Top Sells

Rank Stock Value
1
ETP
Energy Transfer Partners, L.P.
ETP
+$93.5M
2
WPZ
Williams Partners L.P.
WPZ
+$65M
3
BPL
Buckeye Partners, L.P.
BPL
+$48.9M
4
ET icon
Energy Transfer Partners
ET
+$45.2M
5
EPD icon
Enterprise Products Partners
EPD
+$40.2M

Sector Composition

Rank Sector Weight
1 Healthcare 70.8%
2 Financials 1.05%
3 Consumer Discretionary 0.59%
4 Technology 0.58%
5 Consumer Staples 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
76
DELISTED
Sage Therapeutics
SAGE
$360K 0.45%
2,187
-2,047
-48% -$198K
JUNO
77
DELISTED
Juno Therapeutics, Inc.
JUNO
$359K 0.45%
7,860
-6,401
-45% -$319K
INSM icon
78
Insmed
INSM
$23.2B
$358K 0.45%
11,494
-9,304
-45% -$275K
MCRB icon
79
Seres Therapeutics
MCRB
$48M
$358K 0.45%
1,765
+151
+9% +$31K
PRTA icon
80
Prothena Corp
PRTA
$458M
$358K 0.45%
9,552
+3,504
+58% +$178K
XNCR icon
81
Xencor
XNCR
$1.44B
$358K 0.45%
16,314
+433
+3% +$9.39K
KPTI icon
82
Karyopharm Therapeutics
KPTI
$168M
$355K 0.45%
2,465
+80
+3% +$12.8K
SGMO
83
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$354K 0.44%
21,591
-22,391
-51% -$333K
ALNY icon
84
Alnylam Pharmaceuticals
ALNY
$36.3B
$353K 0.44%
2,775
-1,636
-37% -$206K
CBIO
85
Crescent Biopharma
CBIO
$602M
$352K 0.44%
210
-80
-28% -$106K
GTHX
86
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$350K 0.44%
+17,647
New +$379K
PRTK
87
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$350K 0.44%
19,580
+4,854
+33% +$101K
AKBA icon
88
Akebia Therapeutics
AKBA
$327M
$349K 0.44%
23,459
+440
+2% +$7.3K
BCRX icon
89
BioCryst Pharmaceuticals
BCRX
$2.37B
$349K 0.44%
71,081
+14,208
+25% +$68.8K
SIOX
90
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$349K 0.44%
8,286
+6,517
+368% +$292K
ACHN
91
DELISTED
Achillion Pharmaceuticals
ACHN
$349K 0.44%
121,264
+43,831
+57% +$159K
BPMC
92
DELISTED
Blueprint Medicines
BPMC
$348K 0.44%
4,611
-3,884
-46% -$273K
CYTK icon
93
Cytokinetics
CYTK
$11B
$348K 0.44%
42,645
+19,250
+82% +$219K
CALA
94
DELISTED
Calithera Biosciences, Inc
CALA
$348K 0.44%
2,083
+917
+79% +$235K
MLNT
95
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$348K 0.44%
+4,411
New +$326K
ABEO icon
96
Abeona Therapeutics
ABEO
$345M
$346K 0.43%
+874
New +$361K
IMGN
97
DELISTED
Immunogen Inc
IMGN
$346K 0.43%
53,977
-16,058
-23% -$99K
EPZM
98
DELISTED
Epizyme, Inc
EPZM
$346K 0.43%
27,541
+832
+3% +$12.1K
BLUE
99
DELISTED
bluebird bio
BLUE
$345K 0.43%
150
-77
-34% -$156K
JNCE
100
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$344K 0.43%
26,948
+6,650
+33% +$97.8K
2 3
4
5 6

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q4 2017 Portfolio in Review

As of Q4 2017, Virtus ETF Advisers held 303 positions worth $79.7M, down 89% from $742M the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Virtus ETF Advisers withdrew a net $660M in Q4 2017, closing 59 positions and reducing 48 holdings. Its most notable exit was Energy Transfer Partners, L.P., an estimated $93.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 7.9% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Virtus ETF Advisers opened a new position in iShares MSCI India ETF worth $427K.

  • Virtus ETF Advisers's largest Q4 2017 buy was iShares MSCI India ETF: 11,844 shares worth $427K.
  • Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q4 2017, an estimated $1.36M increase.
  • Virtus ETF Advisers's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $1.55M.
  • Virtus ETF Advisers fully exited Energy Transfer Partners, L.P. in Q4 2017, selling an estimated $93.5M.
  • Virtus ETF Advisers's ten largest holdings make up 21% of its $79.7M portfolio in Q4 2017.
  • Virtus ETF Advisers opened 144 new positions and closed 59 in Q4 2017.
  • Virtus ETF Advisers's portfolio value fell 89% quarter-over-quarter to $79.7M.

Based on Virtus ETF Advisers's 13F filing for Q4 2017, filed 14 Feb 2018.